COMPANY

Rhythm Pharmaceuticals

HQ: Boston, MA source · rhythmtx.com ↗ · New England

FDA-approved therapeutic company Clinical Phase 3

56 open jobs · last seen Oct 23, 2026 · 33 sources

Rhythm Pharmaceuticals is a biopharmaceutical company focused on rare neuroendocrine diseases. Rhythm Pharmaceuticals' medicine IMCIVREE (setmelanotide), FDA-approved in 2020, is designed to treat severe obesity caused by an impairment of the MC4R pathway in the hypothalamus. From company website Source · Source · checked 2026-10-19

Sources for this description (2)

Rhythm Pharmaceuticals is a biopharmaceutical company focused on rare neuroendocrine diseases.
- “Rhythm Pharmaceuticals is a global biopharmaceutical company committed to transforming the lives of patients with rare neuroendocrine diseases by rapidly advancing care and precision medicines that address the root cause.” https://rhythmtx.com/ (2026-10-19)
Rhythm Pharmaceuticals' medicine IMCIVREE (setmelanotide), FDA-approved in 2020, is designed to treat severe obesity caused by an impairment of the MC4R pathway in the hypothalamus.
- “Our lead asset, IMCIVREE® (setmelanotide), FDA-approved in 2020, is a precision medicine designed to treat severe obesity caused by an impairment of a pathway in the hypothalamus called the MC4R pathway.” https://rhythmtx.com/about/ (2026-10-19)

Disease: severe obesity

Keywords: rare disease rare diseases metabolic obesity hyperinsulinism Hypothalamic Obesity Prader-Willi Syndrome Genetic Obesity Obesity Associated With Defects in Leptin-melanocortin Pathway Bardet-Biedl Syndrome POMC Deficiency Obesity PCSK1 Deficiency Obesity LEPR Deficiency Obesity Bardet Biedl Syndrome Overweight Hyperphagia Multiple Pituitary Hormone Deficiency Genetic Form Septo-Optic Dysplasia Optic Nerve Hypoplasia Childhood-onset Combined Pituitary Hormone Deficiency Pituitary Stalk Interruption Syndrome POMC Deficiency Alström Syndrome Pro-opiomelanocortin (POMC) Deficiency Obesity Obesity Due to Melanocortin 4 Receptor Deficiency Overweight and Obesity Leptin Receptor Deficiency Obesity Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations Hypertriglyceridemia Renal Insufficiency Genetic Forms of Extreme Obesity Morbid Obesity Obese Setmelanotide RM-493 LB54640 Bivamelagon

Location: Boston, MA · source · Oct 14, 2026

56Open jobs $175.0MRaised (2 yrs)29Trials (company is sponsor)2FDA records (2 yrs)3NIH grants

Hiring

Title	Location (from posting)	Employer posted	First seen
Associate Director, US Patient Marketing	Boston, MA	Not stated	Oct 17, 2026
Head of Global Strategic Sourcing	Boston, MA	Not stated	Oct 11, 2026
Treasury Manager	Boston, MA	Not stated	Oct 11, 2026
Associate Director, Biostatistics	Boston, MA	Not stated	Oct 11, 2026
Senior Director, Biostatistics	Boston, MA	Not stated	Oct 11, 2026

See all 56 jobs

Timeline

Mar 19, 2026 FDA FDA New indication / efficacy supplement: IMCIVREE (setmelanotide acetate) — NDA213793/9, Mar 19, 2026. Applicant at approval: Rhythm Pharmaceuticals, Inc. source ↗
Nov 10, 2025 Trial start Phase 2: A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO) source ↗
Sep 23, 2025 Trial start Phase 3: A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) source ↗
Jul 10, 2025 Raise Follow-on offering: $175M (total, as published), announced Jul 10, 2025. Source: company release on GlobeNewswire. source ↗
Mar 4, 2025 Trial start Phase 2: A Study of Setmelanotide in Patients With Prader-Willi Syndrome source ↗
Dec 20, 2024 FDA FDA New indication / efficacy supplement: IMCIVREE (setmelanotide acetate) — NDA213793/7, Dec 20, 2024. Applicant at approval: Rhythm Pharmaceuticals, Inc. source ↗
Oct 21, 2024 Trial start Phase 3: Open-Label Extension Study of Setmelanotide source ↗
Jul 11, 2024 Trial start Phase 2: A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity source ↗
Mar 5, 2024 Trial start Phase 1/Phase 2: A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment source ↗
Apr 26, 2023 Trial start Phase 3: A Trial of Setmelanotide in Acquired Hypothalamic Obesity source ↗
Mar 8, 2022 Trial start Phase 3: Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity source ↗
Dec 21, 2021 Trial start 3: Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway source ↗
Dec 10, 2021 Trial start Phase 3: EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway source ↗
Nov 30, 2021 Trial start Phase 2: DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway source ↗
Aug 5, 2021 Trial start Phase 4: Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants source ↗
Jun 7, 2021 Trial start Phase 2: Open-Label Study of Setmelanotide in Hypothalamic Obesity source ↗
Jul 9, 2020 Trial start 1: A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment source ↗
Aug 6, 2019 Trial start —: An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic Loss-of-Function Mutations in the POMC, PCSK1 or LEPR Genes source ↗
Nov 23, 2018 Trial start Phase 3: Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity source ↗
Jul 15, 2018 Trial start Phase 2/Phase 3: Long Term Extension Trial of Setmelanotide source ↗
Apr 15, 2018 Trial start —: The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry source ↗
Jan 30, 2018 Trial start Phase 3: Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity source ↗
Aug 15, 2017 Trial start Phase 2: Setmelanotide in a Single Patient With Partial Lipodystrophy source ↗
Feb 14, 2017 Trial start Phase 3: Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity source ↗
Feb 10, 2017 Trial start 2: Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity source ↗

Showing 25 of 31 dated events.

Upcoming milestones

Oct 31, 2026 (ESTIMATED) · Phase 2 · A Study of Setmelanotide in Patients With Prader-Willi Syndrome · NCT06772597
Mar 13, 2027 (ESTIMATED) · Phase 3 · A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) · NCT06760546
May 7, 2027 (ESTIMATED) · Phase 1/Phase 2 · A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment · NCT06239116
Apr 15, 2028 (ESTIMATED) · Phase 2 · A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO) · NCT07156578

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $175.0M. Last 2 years.

Jul 10, 2025 Follow-on offering: $175M (total, as published), announced Jul 10, 2025. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 29

Record	Title	Phase	Status	Start	Primary completion
NCT06239116	A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment	Phase 1/Phase 2	Active, not recruiting	Mar 5, 2024	May 7, 2027 (estimated)
NCT05774756	A Trial of Setmelanotide in Acquired Hypothalamic Obesity	Phase 3	Active, not recruiting	Apr 26, 2023	Mar 18, 2025 (actual)
NCT05093634	EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway	Phase 3	Completed	Dec 10, 2021	Dec 22, 2025 (actual)
NCT06596135	Open-Label Extension Study of Setmelanotide	Phase 3	Completed	Oct 21, 2024	Jun 24, 2026 (actual)
NCT06046443	A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity	Phase 2	Completed	Jul 11, 2024	Feb 9, 2026 (actual)
NCT06772597	A Study of Setmelanotide in Patients With Prader-Willi Syndrome	Phase 2	Active, not recruiting	Mar 4, 2025	Oct 31, 2026 (estimated)
NCT06760546	A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)	Phase 3	Recruiting	Sep 23, 2025	Mar 13, 2027 (estimated)
NCT07156578	A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)	Phase 2	Enrolling by invitation	Nov 10, 2025	Apr 15, 2028 (estimated)
NCT04963231	DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway	Phase 2	Completed	Nov 30, 2021	Aug 4, 2023 (actual)
NCT03651765	Long Term Extension Trial of Setmelanotide	Phase 2/Phase 3	Completed	Jul 15, 2018	Jan 9, 2025 (actual)
NCT04725240	Open-Label Study of Setmelanotide in Hypothalamic Obesity	Phase 2	Completed	Jun 7, 2021	Jun 28, 2022 (actual)
NCT04966741	Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity	Phase 3	Completed	Mar 8, 2022	Sep 18, 2023 (actual)
NCT05194124	Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway	3	Completed	Dec 21, 2021	Oct 19, 2023 (actual)
NCT05046132	Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants	Phase 4	Completed	Aug 5, 2021	Apr 7, 2022 (actual)
NCT03746522	Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity	Phase 3	Completed	Nov 23, 2018	Nov 16, 2020 (actual)
NCT02896192	Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity	Phase 3	Completed	Feb 14, 2017	May 25, 2020 (actual)
NCT03013543	Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity	2	Completed	Feb 10, 2017	Mar 1, 2022 (actual)
NCT01749137	Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants	2	Completed	Jan 14, 2013	Sep 28, 2013 (actual)
NCT02041195	Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients	1	Completed	2014-01	2014-08 (actual)
NCT02311673	Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome	2	Completed	Mar 19, 2015	Oct 26, 2016 (actual)
NCT03287960	Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity	Phase 3	Completed	Jan 30, 2018	Sep 25, 2020 (actual)
NCT02849977	Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers	Not listed	Completed	Sep 28, 2016	Jun 9, 2020 (actual)
NCT05183802	An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)	Not listed	Approved for marketing	Not listed	Not listed
NCT03262610	Setmelanotide in a Single Patient With Partial Lipodystrophy	Phase 2	Completed	Aug 15, 2017	Jan 31, 2018 (actual)
NCT04348175	A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment	1	Completed	Jul 9, 2020	Apr 17, 2021 (actual)
NCT03621007	An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic Loss-of-Function Mutations in the POMC, PCSK1 or LEPR Genes	Not listed	Completed	Aug 6, 2019	Jan 22, 2021 (actual)
NCT03479437	The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry	Not listed	Completed	Apr 15, 2018	Dec 1, 2020 (actual)
NCT01867437	Effects of RM-493 on Energy Expenditure in Obese Individuals	Phase 1	Completed	2013-05	2014-03 (actual)
NCT02431442	Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers	Phase 1	Completed	2012-01	2014-01 (actual)

FDA records (last 2 years)

Mar 19, 2026 FDA New indication / efficacy supplement: IMCIVREE (setmelanotide acetate) — NDA213793/9, Mar 19, 2026. Applicant at approval: Rhythm Pharmaceuticals, Inc. source ↗
Dec 20, 2024 FDA New indication / efficacy supplement: IMCIVREE (setmelanotide acetate) — NDA213793/7, Dec 20, 2024. Applicant at approval: Rhythm Pharmaceuticals, Inc. source ↗

NIH awards 3

Annual award amounts. Total $999K.

Jun 14, 2017 NIH award 5R01FD005094-03 FY2017: $210,406 awarded for that fiscal year; activity R01 (OTHER_NIH); PI GOTTESDIENER, KEITH; recipient as written: RHYTHM PHARMACEUTICALS, INC., BOSTON, MA. Phase II clinical evaluation source ↗
Jul 14, 2016 NIH award 5R01FD005094-02 FY2016: $392,688 awarded for that fiscal year; activity R01 (OTHER_NIH); PI GOTTESDIENER, KEITH; recipient as written: RHYTHM PHARMACEUTICALS, INC., BOSTON, MA. Phase II clinical evaluation source ↗
Jul 10, 2015 NIH award 1R01FD005094-01A1 FY2015: $396,259 awarded for that fiscal year; activity R01 (OTHER_NIH); PI GOTTESDIENER, KEITH; recipient as written: RHYTHM PHARMACEUTICALS, INC., BOSTON, MA. Phase II clinical evaluatio source ↗

Open jobs 56

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Associate Director, US Patient Marketing	Boston, MA	Not stated	Oct 17, 2026	Not stated
Head of Global Strategic Sourcing	Boston, MA	Not stated	Oct 11, 2026	Not stated
Treasury Manager	Boston, MA	Not stated	Oct 11, 2026	Not stated
Associate Director, Biostatistics	Boston, MA	Not stated	Oct 11, 2026	Senior
Senior Director, Biostatistics	Boston, MA	Not stated	Oct 11, 2026	Senior
Senior Statistical Programmer	Boston, MA	Not stated	Oct 11, 2026	Senior
Director, Field Operations & Effectiveness	Boston, MA	Not stated	Oct 11, 2026	Senior
Director, Patient Services Training	Boston, MA	Not stated	Oct 11, 2026	Senior
Executive Medical Director	Boston, MA	Not stated	Oct 11, 2026	Executive
Senior Director, Clinical Pharmacology	Boston, MA	Not stated	Oct 11, 2026	Senior
Senior Manager, Compensation	Boston, MA	Not stated	Oct 11, 2026	Senior
(Senior) Brand Manager Italy	Milan, Italy	Not stated	Oct 11, 2026	Senior
(Senior) Brand Manager, Iberia	Madrid, Spain	Not stated	Oct 11, 2026	Mid
Director, HR Business Partner, International	Amsterdam, Netherlands	Not stated	Oct 11, 2026	Senior
Federated Registry Data Scientist	Madrid; London; Paris; Amsterdam; Munich, UK, France, Netherlands, Germany, Spain, Italy, France	Not stated	Oct 11, 2026	Mid
Federated Registry Program Coordinator	Remote	Not stated	Oct 11, 2026	Entry
Hospital Affairs Director, Germany	Munich, Germany	Not stated	Oct 11, 2026	Senior
Hospital Affairs Lead - Germany (East)	Berlin, Germany	Not stated	Oct 11, 2026	Not stated
Hospital Affairs Lead - Germany (North)	Hamburg, Germany	Not stated	Oct 11, 2026	Senior
Hospital Affairs Lead - Germany (South)	Munich, Germany	Not stated	Oct 11, 2026	Not stated
Hospital Affairs Lead - UK & Ireland (Midlands East)	Leicester, United Kingdom	Not stated	Oct 11, 2026	Not stated
Hospital Affairs Lead - UK & Ireland (Midlands West)	Birmingham, United Kingdom	Not stated	Oct 11, 2026	Not stated
Hospital Affairs Lead, Austria	Innsbruck or Salzburg or Linz, Western Austria, Austria	Not stated	Oct 11, 2026	Senior
Scientific Affairs Manager - Germany (North East)	Remote	Not stated	Oct 11, 2026	Mid
Scientific Affairs Manager - Italy (South)	Naples Metropolitan Area, Italy	Not stated	Oct 11, 2026	Senior
Scientific Affairs Manager, UK - Manchester	Birmingham, United Kingdom	Not stated	Oct 11, 2026	Senior
Senior Director, International Compliance	Amsterdam, London, Munich, Milan, Madrid, Netherlands	Not stated	Oct 11, 2026	Senior
IT Business Analyst, Clinical & Biostatistics	Boston, MA	Not stated	Oct 11, 2026	Mid
IT Business Analyst, G&A	Boston, MA	Not stated	Oct 11, 2026	Mid
IT Business Analyst, Regulatory	Boston, MA	Not stated	Oct 11, 2026	Mid
Senior Regional Account Manager	Boston, MA	Not stated	Oct 11, 2026	Senior
Senior Medical Communications Writer - Medical Affairs, North America	Boston, MA	Not stated	Oct 11, 2026	Senior
Director, Program Management	Boston, MA	Not stated	Oct 11, 2026	Senior
Associate Director, Medical Writing	Boston, MA	Not stated	Oct 11, 2026	Senior
Director, Regulatory CMC	Boston, MA	Not stated	Oct 11, 2026	Senior
Director, Nonclinical Development - ADME/DMPK	Boston, MA	Not stated	Oct 11, 2026	Senior
Director, Nonclinical Development - Toxicology	Boston, MA	Not stated	Oct 11, 2026	Senior
Territory Manager (Eastern Canada)	Montreal, QC, Canada	Not stated	Oct 11, 2026	Mid
Territory Manager, BBS (Northwest - Seattle)	Seattle, WA	Not stated	Oct 11, 2026	Not stated
Territory Manager, BBS (Sierra West)	San Francisco, CA	Not stated	Oct 11, 2026	Mid
Territory Manager, BBS (Southwest)	Los Angeles, CA	Not stated	Oct 11, 2026	Mid
Senior Publications Manager	Boston, MA	Not stated	Oct 11, 2026	Senior
Quality Assurance Specialist	Amsterdam, Netherlands	Not stated	Oct 11, 2026	Mid
Senior Director, Analytical Development & Quality Control	Boston, MA	Not stated	Oct 11, 2026	Senior
Senior Manager, Analytical Chemistry	Boston, MA	Not stated	Oct 11, 2026	Senior
Senior Manager, Drug Substance	Boston, MA	Not stated	Oct 11, 2026	Senior
Senior Manager, Quality Assurance/Qualified Person	Amsterdam, Netherlands	Not stated	Oct 11, 2026	Senior
Senior Manager, Swiss Responsible Person and GDP Quality Assurance	Zug, Switzerland	Not stated	Oct 11, 2026	Senior
Medical Science Liaison (Senior Manager, Field Medical) - New York Metro	New York, NY	Not stated	Oct 11, 2026	Senior
Medical Science Liaison (Senior Manager, Field Medical) - Northwest	Seattle, WA	Not stated	Oct 11, 2026	Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

All 56 jobs →

Connect

See your connections at Rhythm Pharmaceuticals on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12